TARS insider transactions
Tarsus Pharmaceuticals Inc. (TARS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for TARS
- Director Pyott David E I converted options into 201 shares (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Link William J Phd converted options into 201 shares and sold $979,744 worth of shares (12,500 units at $78.38) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 94,487 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Yarno Wendy L converted options into 302 shares, increasing direct ownership by 2% to 16,956 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- President/CEO and Board Chair Azamian Bobak R. sold $905,600 worth of shares (10,000 units at $90.56) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Operating Officer Neervannan Seshadri sold $387,940 worth of shares (4,564 units at $85.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 78,532 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Medical Officer Lin Elizabeth Yeu sold $1,220,885 worth of shares (13,953 units at $87.50) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 2,547 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- President/CEO and Board Chair Azamian Bobak R. sold $800,600 worth of shares (10,000 units at $80.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Medical Officer Lin Elizabeth Yeu sold $897,990 worth of shares (11,578 units at $77.56) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 13,320 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Chaudhuri Bhaskar4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Morrison Scott W4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Goldberg Andrew D.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Goodrich Katherine4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Yarno Wendy L4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Pyott David E I4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Link William J Phd4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- President/CEO and Board Chair Azamian Bobak R. sold $615,488 worth of shares (10,000 units at $61.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Officer Farrow Jeffrey S converted options into 27,881 shares and sold $877,436 worth of shares (14,396 units at $60.95), increasing direct ownership by 31% to 56,801 units (SEC Form 4) (withholding tax)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Goodrich Katherine sold $183,384 worth of shares (2,954 units at $62.08) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 2,233 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Link William J Phd sold $776,495 worth of shares (12,500 units at $62.12) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 106,786 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Morrison Scott W converted options into 2,954 shares, increasing direct ownership by 63% to 7,638 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Chaudhuri Bhaskar converted options into 2,954 shares, increasing direct ownership by 34% to 11,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Yarno Wendy L converted options into 2,954 shares, increasing direct ownership by 22% to 16,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Goodrich Katherine converted options into 2,954 shares, increasing direct ownership by 132% to 5,187 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Link William J Phd converted options into 2,954 shares, increasing direct ownership by 3% to 119,286 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Goldberg Andrew D. converted options into 2,954 shares, increasing direct ownership by 18% to 19,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Pyott David E I converted options into 1,383 shares (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Neervannan Seshadri4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Whitfield Dianne C.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Wahl Bryan4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Neervannan Seshadri4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Mottiwala Aziz4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Lin Elizabeth Yeu4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Farrow Jeffrey S4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Azamian Bobak R.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Link William J Phd4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Human Resources Officer Whitfield Dianne C. converted options into 23,909 shares, increasing direct ownership by 102% to 47,302 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- General Counsel Wahl Bryan converted options into 24,236 shares, increasing direct ownership by 46% to 76,399 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Operating Officer Neervannan Seshadri converted options into 26,287 shares, increasing direct ownership by 37% to 97,104 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Commercial Officer Mottiwala Aziz converted options into 26,482 shares, increasing direct ownership by 55% to 74,536 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Officer Farrow Jeffrey S converted options into 13,042 shares, increasing direct ownership by 36% to 49,746 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- President/CEO and Board Chair Azamian Bobak R. converted options into 66,274 shares, increasing direct ownership by 3,787% to 68,024 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Medical Officer Lin Elizabeth Yeu converted options into 2,511 shares, increasing direct ownership by 11% to 24,452 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by General Counsel Wahl Bryan4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Officer Farrow Jeffrey S4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Chief Commercial Officer Mottiwala Aziz4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Chief Human Resources Officer Whitfield Dianne C.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Chief Operating Officer Neervannan Seshadri4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by President/CEO and Board Chair Azamian Bobak R.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Lin Elizabeth Yeu4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Operating Officer Neervannan Seshadri sold $641,421 worth of shares (8,366 units at $76.67), decreasing direct ownership by 11% to 70,817 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SEC Form 4 filed by Director Pyott David E I4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- New insider Pyott David E I claimed ownership of 7,991 shares (SEC Form 3)3 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Goodrich Katherine converted options into 2,233 shares (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Human Resources Officer Whitfield Dianne C. sold $1,255,684 worth of shares (15,565 units at $80.67), decreasing direct ownership by 40% to 23,393 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- President/CEO and Board Chair Azamian Bobak R. sold $495,089 worth of shares (6,000 units at $82.51) (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Operating Officer Neervannan Seshadri gifted 950 shares and received a gift of 475 shares, decreasing direct ownership by 1% to 79,183 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Human Resources Officer Whitfield Dianne C. sold $592,500 worth of shares (7,397 units at $80.10), decreasing direct ownership by 16% to 38,958 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Director Link William J Phd sold $1,864,678 worth of shares (22,946 units at $81.26), decreasing direct ownership by 9% to 128,832 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- Chief Medical Officer Lin Elizabeth Yeu converted options into 6,819 shares and sold $165,201 worth of shares (2,078 units at $79.50), increasing direct ownership by 28% to 21,941 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- President/CEO and Board Chair Azamian Bobak R. gifted 51,885 shares (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)